Ipamorelin 5 mg

Popis

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor (GHSR-1a) agonist belonging to the GHRP (growth hormone-releasing peptide) family. Unlike recombinant growth hormone, Ipamorelin stimulates the body’s own pulsatile growth hormone secretion through activation of the ghrelin receptor, allowing researchers to investigate physiological GH release rather than direct hormone replacement.

One of the defining characteristics of Ipamorelin is its high receptor selectivity. Compared with earlier growth hormone secretagogues such as GHRP-2 and GHRP-6, published endocrine studies have reported substantially less stimulation of ACTH, cortisol and prolactin, making Ipamorelin one of the most selective compounds within this peptide class.

Looking to buy Ipamorelin in Europe? LIFE Peptide supplies high-purity Ipamorelin for laboratory research with reliable EU-wide shipping.

Why Ipamorelin matters in growth hormone research

Ipamorelin has become an important research peptide because it allows investigators to study growth hormone physiology while producing comparatively limited activation of other pituitary hormone pathways.

Published research has investigated Ipamorelin in relation to:

• physiological growth hormone release
• Regulace IGF-1
• ghrelin receptor signalling
• fyziologie endokrinního systému
• body composition
• muscle protein metabolism
• recovery physiology
• ageing-related endocrine changes

Unlike many earlier GHRPs, Ipamorelin is primarily valued for its selectivity rather than the absolute magnitude of GH release, making it an important comparator in endocrine research.

How Ipamorelin works

Ipamorelin binds selectively to the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. Activation of this receptor stimulates pulsatile secretion of endogenous growth hormone from the anterior pituitary. Unlike direct GH administration, this mechanism preserves the body’s own endocrine regulation and feedback systems, making Ipamorelin useful for investigating physiological growth hormone dynamics rather than pharmacological hormone replacement.

Published endocrine studies have consistently highlighted another distinguishing characteristic: minimal stimulation of ACTH, cortisol and prolactin compared with earlier GHRPs.

What makes Ipamorelin different from other GH secretagogues?

Ipamorelin

• selective ghrelin receptor agonist
• highly selective GH release
• minimal ACTH stimulation
• minimal cortisol response
• minimal prolactin response

GHRP-2

• stronger overall GH release
• broader pituitary stimulation
• more endocrine cross-activation

GHRP-6

• stimulates GH release
• often associated with marked appetite stimulation
• broader hormonal profile

CJC-1295 with or without DAC

• Analogon GHRH
• stimulates GH through a different receptor pathway
• frequently investigated alongside Ipamorelin because the mechanisms complement one another

Human clinical and endocrine research

Unlike GLP-1 receptor agonists, Ipamorelin has not been investigated through large cardiovascular or obesity outcome programmes. Instead, published human studies have focused primarily on endocrine physiology, receptor pharmacology and growth hormone secretion.

Clinical investigations have demonstrated that Ipamorelin produces dose-dependent increases in endogenous growth hormone release while exhibiting substantially greater endocrine selectivity than earlier growth hormone secretagogues. In multiple human studies, little or no clinically relevant stimulation of cortisol, ACTH or prolactin was observed, distinguishing Ipamorelin from several first-generation GHRPs.

Although Ipamorelin was later investigated for postoperative ileus, that programme did not demonstrate sufficient efficacy for further pharmaceutical development. Its scientific value today lies primarily in endocrine and growth hormone research rather than as an approved therapeutic agent.

Publikované bezpečnostní poznatky

Published human studies generally describe Ipamorelin as being well tolerated during clinical investigation. Reported adverse events have typically been mild, with the overall safety profile reflecting its relatively selective receptor activity.

From an endocrine perspective, one of the most important observations has been the limited stimulation of cortisol, ACTH and prolactin compared with several earlier growth hormone secretagogues. This endocrine selectivity remains one of the defining characteristics of Ipamorelin in the published literature.

Research protocols reported in the literature

Published clinical studies have investigated Ipamorelin using multiple dosing strategies depending on study objectives, including endocrine physiology, postoperative recovery and pharmacodynamic evaluation.

Rather than supporting a single standard protocol, the published literature reflects a range of experimental designs intended to characterise growth hormone secretion, receptor selectivity and endocrine responses under controlled conditions.

The dosing schedules reported in published studies are summaries of research methodology and are not instructions for use of this product.

Klíčové publikované studie

• Raun K et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998.

The landmark paper introducing Ipamorelin and demonstrating its highly selective stimulation of growth hormone release with minimal effects on ACTH, cortisol and prolactin.

• Svensson J et al. Pharmacokinetic–pharmacodynamic modelling of Ipamorelin in healthy volunteers. Pharmaceutical Research. 1999.

A foundational human study describing dose-response relationships, growth hormone release and pharmacodynamic characteristics.

• Bowers CY. Growth Hormone Secretagogues.

A comprehensive review covering the physiology of ghrelin receptor agonists, receptor biology and the role of peptides such as Ipamorelin within the broader GH secretagogue family.

• Ghigo E et al. Growth Hormone Secretagogues: Clinical Pharmacology and Endocrine Physiology.

An overview of endocrine mechanisms, receptor pharmacology and clinical development across the GH secretagogue class.

Často kladené dotazy

What is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin receptor (GHSR-1a) to stimulate physiological release of endogenous growth hormone. Unlike recombinant GH, it promotes the body’s own pulsatile GH secretion through pituitary signalling.

How does Ipamorelin differ from GHRP-2 and GHRP-6?

Ipamorelin is considered the most selective member of the classic GHRP family. Published endocrine studies have shown minimal stimulation of ACTH, cortisol and prolactin compared with earlier growth hormone secretagogues, making it particularly valuable for research focused on selective GH release.

Why is Ipamorelin frequently combined with CJC-1295?

Although both peptides influence growth hormone secretion, they act through different receptor systems. CJC-1295 is a GHRH analogue, while Ipamorelin activates the ghrelin receptor. Researchers have investigated this complementary receptor activation to better understand physiological GH pulsatility and endocrine signalling.

What research areas commonly investigate Ipamorelin?

Published research has explored Ipamorelin in endocrine physiology, growth hormone regulation, IGF-1 signalling, body composition, muscle metabolism, ageing-related endocrine changes and ghrelin receptor biology. Its receptor selectivity makes it one of the most widely studied peptides within the GH secretagogue class.

Can I buy Ipamorelin in Europe?

Yes. We ship Ipamorelin to most European countries using reliable courier services. Available shipping methods and delivery times are shown during checkout based on your destination.

Is Ipamorelin intended for human use?

No. Ipamorelin supplied by LIFE Peptide is provided strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published studies on this page summarises the scientific literature relating to the Ipamorelin molecule rather than the intended use of this product.

Vlastnosti produktu

Aplikace: laboratorní a analytický výzkum
Použití omezené: není určeno k lidské spotřebě; pro lékařské, veterinární ani kosmetické použití
Vyrobeno v zařízeních splňujících správnou výrobní praxi (GMP) za přísných protokolů kontroly kvality.
Každá šarže je po výrobě pečlivě laboratorně testována (Certifikát o analýze najdete pod obrázky produktů).
Lyofilizováno (sušeno mrazem) pro maximální stabilitu a prodlouženou trvanlivost.
Uzavřeno ve sterilních lahvičkách, připraveno k rekonstituci.
Purity: ≥ 99.90% , HPLC tested, independently confirmed high purity and identity consistency. Zobrazit ověření třetí stranou.
Vzhled: bílý lyofilizovaný prášek
Molekulární vzorec: C₄₀H₅₂N₁₀O₆
Molecular weight: 768.93

ÚložištěNeotevřené lyofilizované lahvičky jsou nejlépe skladovány chlazené při 2–8 °C, což je metoda skladování potvrzená naším výrobním partnerem a vhodná až po dobu 24 měsíců. Preferuje se chlazení, protože minimalizuje zbytečné cykly zmrazování a rozmrazování během běžné manipulace. Pokud je vyžadováno podstatně delší skladování, lze zmrazené uchovávat i neotevřené lyofilizované lahvičky. Po rekonstituci vždy skladujte při 2–8 °C a nezmrazujte.

Rekonstituce a manipulace

Ipamorelin is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with bakteriostatická voda před použitím. Pro zachování strukturální integrity přidejte zvolené rozpouštědlo pomalu po vnitřní stěně lahvičky namísto přímo na peptidový prášek a vyhněte se prudkému protřepávání. Jemné kroužení je obecně dostačující, jakmile se peptid zcela rozpustí. Standardní laboratorní postupy zahrnují také ponechání chlazených lahviček dosáhnout pokojové teploty před rekonstitucí, aby se minimalizovala kondenzace uvnitř lahvičky.

Pro další pokyny k výběru rozpouštědla, plánování koncentrací a skladování viz úplné Průvodce rekonstitucí peptidů a Kalkulačka rekonstituce.

Vybrané výzkumné reference

• Raun K et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998.
• Smith RG et al. “Growth hormone secretagogues: physiology and clinical relevance.” Trends in Endocrinology & Metabolism, 2005.
• Bowers CY. “GH releasing peptides — structure and kinetics.” Journal of Pediatric Endocrinology and Metabolism, 1993.
• Hansen BS et al. “Ipamorelin, a new potent growth hormone-releasing peptide.” American Journal of Physiology, 1999.

Související výzkumný kontext

Ipamorelin belongs to the growth hormone secretagogue research class, which includes compounds investigated for endocrine signaling and GH-axis modulation.
Pro širší přehled signálních drah GH a srovnávacích mechanismů peptidů viz naše Průvodce výzkumem růstových hormonových peptidů.
Researchers studying GH pathway interaction may also examine:
CJC-1295 (GHRH analogue research peptide)
GHRP-2
GHRP-6
Procházet všechny sloučeniny v Sekre pagy růstového hormonu.
Výzkumníci zkoumající endokrinní regulaci mohou také zkoumat sloučeniny v Metabolický výzkum, včetně GLP-1 a agonistů inkretinů s více dráhami.

POZNÁMKAToto je pouze pro vzdělávací účely a nepředstavuje lékařskou radu.

Zřeknutí se odpovědnosti
Tento produkt je prodáván pouze pro výzkumné účely. Není určen k diagnostice, léčbě, vyléčení nebo prevenci jakýchkoli onemocnění. Kupující přebírá plnou odpovědnost za řádnou manipulaci a použití.